Seattle Genetics to Present at the Cowen 40th Annual Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Feb 26, 2020--
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Cowen 40 th Annual Healthcare Conference on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.
About Seattle Genetics
Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative medicines targeting cancer to make a meaningful difference in people’s lives. ADCETRIS ® (brentuximab vedotin) and PADCEV TM (enfortumab vedotin-ejfv) use the company’s industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. In addition, investigational agent tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer and in clinical development for metastatic colorectal cancer. The company is headquartered in Bothell, Washington, and has offices in California, Switzerland and the European Union. For more information on our robust pipeline, visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter.
View source version on businesswire.com:https://www.businesswire.com/news/home/20200226005071/en/
KEYWORD: WASHINGTON UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: ONCOLOGY HEALTH CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Seattle Genetics, Inc.
Copyright Business Wire 2020.
PUB: 02/26/2020 08:00 AM/DISC: 02/26/2020 08:00 AM